Patients with chronic lumbago | Patients without chronic lumbago | P value | |
N | 21 | 31 | |
Age, years | 73.1 ± 5.0 | 70.1 ± 8.3 | 0.21 |
Male, % | 32 | 57 | 0.06 |
Duration from onset | 6.7 ± 4.8 | 5.7 ± 4.1 | 0.36 |
BMI, kg/mm2 | 21.3 ± 3.5 | 21.1 ± 3.0 | 0.83 |
Waist hip ratio | 0.85 ± 0.11 | 0.85 ± 0.08 | 0.70 |
College graduate (%) | 66.7 | 74.2 | 0.39 |
High economic status (%) | 19.0 | 29.0 | 0.57 |
Hoehn-Yhar stage | 3.5 ± 0.8 | 2.7 ± 0.9 | 0.00 |
Medications | |||
Levodopa (mg) | 513 ± 175 | 364 ± 199 | 0.00 |
Pramipexoe (mg) | 1.8 ± 1.2 (n = 6) | 1.9 ± 0.9 (n = 17) | 1.00 |
Ropinirole (mg) | 10.4 ± 4.3 (n = 5) | 10.0 ± 3.1 (n = 6) | 0.46 |
Selegiline (%) | 28.6 | 32.3 | 0.78 |
Entacapone (%) | 19.0 | 6.5 | 0.28 |
Amantagine (%) | 47.6 | 35.5 | 0.35 |
Zonisamide (%) | 14.3 | 6.5 | 0.25 |
Trihexyphenidile (%) | 27.8 | 4.8 | 0.02 |
Donepezil (%) | 19.0 | 6.5 | 0.16 |
BMI: body mass index |
|
|
|